Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
desogestrel + ethinylestradiol + interferon-beta 1a
- Development stage
- Unknown
- Lead developer
- Sant'Andrea Hospital
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Subcutaneous
01
Overview
This investigational combination therapy involves the administration of oral estroprogestins (specifically desogestrel and ethinylestradiol) in conjunction with subcutaneous interferon-beta 1a (Rebif) for the treatment of relapsing-remitting multiple sclerosis (RRMS). Developed and studied at the MS Centre Sant'Andrea Hospital (Sapienza University of Rome), the treatment explores the hypothesis that sex hormones exert immunomodulatory and neuroprotective effects that can synergize with standard disease-modifying therapies. The combination was evaluated in a Phase 2 clinical trial (NCT00151801) using two different estroprogestin dosing regimens (Mercilon and Gracial) to assess safety, tolerability, and efficacy on MRI-detected brain lesions and cognitive function in female patients.
- Brand names
- MercilonGracial
- Other names
- estroprogestins + interferon-beta 1aoral contraceptives + Rebif
02
Targets
ER (Estrogen receptor)IFNAR (Immune system modulation via type I interferon receptor)PR (Progesterone receptor)IFNAR1 (Interferon alpha/beta receptor 1)IFNAR2 (Interferon alpha/beta receptor subunit 2)
Beyond the preview
Go deeper on desogestrel + ethinylestradiol + interferon-beta 1a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on desogestrel + ethinylestradiol + interferon-beta 1a.